The Comparative Effect of Nisin and Thioridazine as Potential Anticancer Agents on Hepatocellular Carcinoma

Noha El-Sayed Ibrahim*1, Heba Morsy2, Marwa Abdelgwad2

Abstract

Background: Hepatocellular carcinoma is a major health problem worldwide especially in Egypt. It accounts for the fifth common cancer and the second cause of death among different cancers. This study investigated the efficacy and molecular mechanism of Nisin and/or Thioridazine as anticancer treatment on human liver cancer HepG2 cell line.

Methods: Nisin and Thioridazine were applied for 24 h on human liver cancer cell line (HepG2). 3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay was done to assess the cytotoxicity of Nisin and Thioridazine. Quantitative reverse transcriptase polymerase chain reaction (qRT-PCR) was used for the assessment of PI3K, AKT, SIRT-1, and NRF2 expression in the treated cell line. The protein level of reactive oxygen species (ROS) and vascular endothelial growth factor (VEGF) was measured in the collected media by ELISA technique. Western blot analysis was done for, tAKT, pAKT, tPI3K, and pPI3K.

Results: Cell proliferation results showed that compared with the untreated cancer, Nisin and/or Thioridazine treated groups had decreased cell proliferation (p value< 0.0001). Nisin and/or Thioridazine decreased PI3K/AKT mRNA and protein expression in hepatocellular carcinoma cells (HCC). Also Nisin and/or Thioridazine decreased anti-oxidative SIRT1/NRF2 mRNA expression. ROS level highly increased with Nisin and/or Thioridazine treatment in contrast to VEGF protein level which was highly decreased.

Conclusions: These results introduce Nisin and Thioridazine as new therapeutic lines in HCC.

Keywords: Hepatocellular carcinoma, Nisin, Thioridazine.

Introduction

Hepatocellular carcinoma (HCC) is one of the most common cancers in the world. According to death in men due to cancer, HCC represents the sixth cause in developed countries and the second cause in less developed countries. Annually, HCC leads to over 1 million deaths (1). Hepatocellular carcinoma (HCC) diagnosis is usually being at the late stage of the disease, especially in developing countries where the screening processes is absent. Although marked progress has been achieved in the cancer therapy, but the different lines of treatment including surgery and chemotheraphy and radiation therapy cause normal cell damage and further morbidity (2,3). In recent years, many researches have been designed to improve patient survival by trying new lines of treatment.

Nisin is an antimicrobial agent produced by specific Gram-positive bacteria including Lactococcus and Streptococcus species (4,5). Over the past few decades, Nisin has been used as a natural bio preservative in food industry (5). Recently, Nisin has been participated in different biomedical fields (6). Nisin as a cytotoxic and antitumor agent was been widely investigated in
last few years. Nisin mediated these effects through activation of preferential apoptosis, cell cycle arrest, and reducing cell proliferation (7).

Thioridazine (TDZ) was originally used as antipsychotic drug (8,9), and used to treat microbial resistance (10,11). Recently, many researches proved anticancer activity of Thioridazine through induction of apoptosis (12) and inhibition of angiogenesis (13) and metastasis (14). Several preclinical studies described the potent treatment effect of Thioridazine on various types of cancer cells. Studies have revealed that Thioridazine has antiproliferative activity and promote apoptosis in gastric cancer, cervical cancer, endometrial cancer, breast cancer, neuroblastoma, glioma, leukemia, and ovarian cancer (13, 15-20). These studies have demonstrated Thioridazine’s anticancer, multidrug resistance-reversing and apoptosis-inducing properties in various tumor cell lines (21-24).

Depend on the previous introduction, we thought to study anticancer effect of each of Nisin, Thioridazine and combinations of both on HepG2 cell line.

Materials and Methods

**HepG-2 cell line and drugs preparation**

Hepatocellular carcinoma cell line (HepG-2) was supplied from Cell Culture Department-VACSERA- EGYPT. HepG-2 cells (Hepatocellular carcinoma) were imported from the “American Type Culture Collection (ATCC)”, complete medium containing Dulbecco’s modified Eagle’s medium (DMEM) supplemented with 10% fetal bovine serum (FBS) and antibiotics (100 U/ml penicillin and 100 mg/ml streptomycin) in 5% CO2 incubator at 37 °C. Nisin (N5764-1G, Nisin from *Lactococcus* lactis (Sigma) (lot # BCBJ3400V) and Thioridazine (1662504-Thioridazine,10-[2-(1-Methyl-2-piperidinyl)ethyl]-2-(methylthio)-10H- phenothiazine from Merck were dissolved in dimethyl sulfoxide (DMSO), and then added to fresh culture medium.

**The cell viability assay**

The HepG-2 cells were cultivated in three 96-well tissue culture plates containing 10³ cells/ml per well. The cells were incubated for 24 h before adding the drugs. The optimal cell number for cytotoxicity assays was determined in preliminary experiments. At the end of the incubation period, the medium was removed and 100 µg/mL of Nisin and 7.5 µM/ml of Thioridazine were added to wells for 24 h. Following 24 h, 20 µL of MTT (5 mg/mL) (TACSTM TREVIGEN1 8405 Helgerman Ct. Gaithersburg) were added to cells and incubated for a further 4 h at 37 °C. The medium was removed and 100 µL formazan was added to each well. After overnight incubation, the absorbance values were measured at a range from 490 to 630 nm using an ELISA reader (Dynatech MRX 5000; Dynex, Chantilly, VA).

**Real time PCR of all studied genes**

The HepG-2 cells were cultivated in 50 cm² flask containing 10⁶ cells/ml per flask. Before adding the drugs, the cells were incubated in RPMI 1640 medium supplemented with 10% fetal bovine serum (FBS) and 1% penicillin–streptomycin liquid for 24 h. The HepG-2 cells were divided into four groups as following:

1. HepG-2 cell lines as an untreated cell
2. HepG-2 cell lines treated with Nisin of concentration 100 µg/mL (25) for 24 hour
3. HepG-2 cell lines treated with Thioridazine of concentration 7.5 µM/ml (26) for 24 hour
4. HepG-2 cell lines treated with combination of Nisin and Thioridazine for 24 hour.

Total RNA was extracted from cultivated cells of all studied groups with RNA easy Mini Kit (Qiagen) according to the manufacturer’s instructions. Quantitation and purity assessment for RNA samples were done using the Nano Drop® (ND)-1000 spectrophotometer (Nano Drop Technologies, Inc. Wilmington, USA). The extracted RNA then stored at −80 °C until use.

SensiFAST™ SYBR® Hi-ROX One-Step Kit, catalog no. PI-50217 V had been formulated for highly reproducible first-strand cDNA synthesis and subsequent real-time PCR in a single tube in a 48-well plate using the Step One instrument (Applied Biosystem, USA).

Normalization for variation in the expression of each target gene was performed referring to the mean critical threshold (CT) values of glyceraldehyde 3-phosphate dehydrogenase (β-actin) housekeeping gene expression by the ΔΔCt method. Primers sequence for all studied genes was listed as following in Table 1.
Table 1. Primers used for RT-qPCR.

<table>
<thead>
<tr>
<th>Gene</th>
<th>Forward (5'-3')</th>
<th>Reverse (5'-3')</th>
</tr>
</thead>
<tbody>
<tr>
<td>PI3K</td>
<td>GAATCCAATGGGAATGTT</td>
<td>GGGAGGGTAATAATAAGGT</td>
</tr>
<tr>
<td>AKT</td>
<td>TGCAGCATCGCTTCTTGT</td>
<td>TCTGGGCGTGAACTCCT</td>
</tr>
<tr>
<td>SIRT-1</td>
<td>CAGGAAGTACAAAAAGCCATC</td>
<td>AATCTCAAATGACATGCAGTG</td>
</tr>
<tr>
<td>Nrf2</td>
<td>ATGGATTTGATTGACATCTTT</td>
<td>ACTGAGCCTGATTAGFAGCAAAT</td>
</tr>
<tr>
<td>GAPDH</td>
<td>CAAGGTCATCCATGACAA</td>
<td>GTCCACCACCCCTTGCTG</td>
</tr>
</tbody>
</table>

**Assessment of ROS and VEGF by ELISA**
The level of reactive oxygen species (ROS) and vascular endothelial growth factor (VEGF) was measured in the collected media using ROS ELISA kit (AMSBIO, Catalog No.: AMS.E01R0021) and VEGF ELISA kit (MyBioSource, Catalog No.: MBS355343). The spectrophotometric absorbance was assessed at 450 nm in accordance with the manufacturer’s instructions. The results were expressed as IU/mL.

**Western blot analysis for tAKT, pAKT, tPI3K and pPI3K**
After drug exposure for 24 hours, RIPA buffer (Bio BASIC INC., Markham, Ontario, Canada) was used to extract all proteins from collected cells. Bradford Protein Assay Kit (SK3041) for quantitative protein analysis (Bio BASIC INC., Markham, Ontario, Canada). A Bradford assay was performed according to manufacturer instructions.

Total proteins were separated by 10% SDS-PAGE then electro transferred to polyvinylidene fluoride (PVDF) membranes. The membranes were blocked for 2 hours with 5% non-fat dry milk then incubated with primary antibodies at dilution (1:200) at 4 °C overnight. After being washed twice with PBS, the membranes were incubated for 1 hour using HRP-conjugated secondary antibodies at dilution (1:500). Finally, an enhanced luminol-based chemiluminescent (ECL) kit was used to detect the target proteins. Image analysis software was used to read the band intensity of the target proteins against control sample by total protein normalization on the ChemiDoc MP imager.

**Statistical methods**
Data were coded and entered using Graph Pad Prism 7. Data was summarized using mean and standard deviation. Comparisons between groups were done using analysis of variance (ANOVA) Tukey’s multiple comparisons test when comparing more than 2 groups (27).

**Results**

**Microscopic pictures of different cultured cancer cells**
Showing effect of Nisin and/or Thioridazine treatment on highly proliferative viable cancer cells which became less proliferative and less viable cancer cells (Fig. 1).

**Fig. 1.** Light microscopy imaging. Cancer cells in different study groups. (A) Control cells showing highly proliferative viable control untreated cancer cells. (B) Less proliferative and less viable treated cancer cells with Nisin. (C) Less proliferative and less viable treated cancer cells with Thioridazine. (D) Less proliferative and less viable treated cancer cells with Nisin and Thioridazine (black arrow).
Cancer cells proliferation using MTT assay

Cell proliferation was determined at 24 post treatment with Nisin and Thioridazine treatment. There is a significant decrease in cell proliferation in Cancer cells treated with Nisin (2.0 ± 0.52), Cancer cells treated with Thioridazine (0.99 ± 0.42) and Cancer cells treated with Nisin and Thioridazine (0.46 ± 0.21) groups compared to untreated cancer group (4.9 ± 1.2). (p value < 0.0001). There is also significant decrease between Cancer cells treated with Nisin and Thioridazine and cancer cells treated with Thioridazine against untreated cancer cells treated with Nisin (p value = 0.02 and < 0.0001 respectively) (Fig. 2).

Fig. 2. Measurement of cell proliferations in different study groups using MTT assay.

Data were expressed as Mean ± SD, p value < 0.05 was significant.

(*) Denotes significant difference versus cancer group.
(#) Denotes significant difference versus cancer+Nisin group.

Inhibition of PI3K/AKT signaling pathway in HepG-2 cell line

To examine if Nisin and/or Thioradizine affect PI3K/AKT signalling in HCC cells, after 24 hours from treatment of HepG-2 cell line with Nisin and/or Thioradizine we measure mRNA and protein expression for each of them.

PI3K and AKT mRNA expression

Figure 3A shows that treatment with Nisin or Thioradizine decreased PIK3 mRNA expression in HepG2 cells (0.94 ± 0.47, 0.56 ± 0.26) respectively compared with that in the untreated cancer cells (1.32 ± 0.34). This decrease was no significant with Nisin and significant with Thioradizine (p value < 0.001).

The treatment with Nisin and Thioradizine decreased significantly PIK3 mRNA expression (0.31 ± 0.05) compared with untreated cancer group (p value < 0.0001).

Figure 3B shows that treatment with Nisin or Thioradizine decreased AKT mRNA expression in HepG2 cells (1.57 ± 0.28, 0.49 ± 0.03) respectively compared with that in the untreated cancer cells (2.5 ± 0.07) (p < 0.05).

The treatment with Nisin and Thioradizine decreased significantly AKT mRNA expression (0.49 ± 0.08) compared with those in the groups treated with Nisin only and untreated cancer group (p value < 0.0001).

PI3K and AKT protein expression

The protein levels of p-PI3K and p-AKT were decreased significantly when HepG2 cells were treated with the combination of Nisin and Thioradizine (0.71 ± 0.22, 1.34 ± 0.15)
respectively compared with those in the groups treated with Nisin (1.69 ± 0.15, 2.45 ± 0.24) or Thioridazine (1.42 ± 0.26, 2.3 ± 0.19) only, and the untreated cancer group (2.55 ± 0.16, 3.7 ± 0.2) (p value< 0.0001) (Figs. 4 and 5).

Fig. 3. PI3K expression (A) and AKT (B) among different study groups. Data were expressed as Mean ± SD, p value< 0.05 was significant. (*) Denotes significant difference versus cancer group. (#) Denotes significant difference versus cancer+Nisin group.

Fig. 4. Protein level of pPI3K (A) and pAKT (B) in different study groups. Data were expressed as Mean ± SD, p value< 0.05 was significant. (*) Denotes significant difference versus cancer group. (#) Denotes significant difference versus cancer+Nisin group. ($) Denotes significant difference versus cancer+Thioridazine group.
Anti-oxidative stress effect of Nisin and Thioridazine

Effect of Nisin and Thioridazine on SIRT1

The expression levels of SIRT1 were decreased significantly when HepG2 cells were treated with the combination of Nisin and Thioridazine (0.62 \pm 0.18) and treated with Thioridazine (1.6 \pm 0.56) only compared to the untreated cancer group (2.5 \pm 0.71), p value < 0.0001 and 0.02, respectively, (Fig. 6 A).

There is significant difference between the group treated with drug combination against each of group treated with Nisin (1.9 \pm 0.53) and that treated with Thioridazine, p value = 0.001 and 0.02, respectively.

There is no significant difference between the groups treated with Nisin or Thioridazine (p value > 0.05).

NRF2 mRNA expression

There is statistical significant decrease in Nrf2 gene expression in Cancer group treated with Nisin (1.38 \pm 0.18), Cancer group treated with Thioridazine (1.02 \pm 0.45) Cancer group treated with Nisin and Thioridazine (0.45 \pm 0.32) groups compared to untreated cancer group (2.3 \pm 0.76), p value < 0.0001.

There is also significant difference between Cancer group treated with Nisin and Thioridazine and Cancer group treated with Nisin (p value = 0.01) (Fig. 6 B).

---

**Fig. 5.** Western blot bands of PI3K and AKT proteins in different study groups.

**Fig. 6 A, B:** SIRT 1 and Nrf2 gene expression in different study groups. 
Data were expressed as Mean \pm SD, p value < 0.05 was significant.

(*) Denotes significant difference versus cancer group.

(#) Denotes significant difference versus cancer+Nisin group.

($) Denotes significant difference versus cancer+Thioridazine group.
**Reactive oxygen species level**

After 24 hours, there is Statistical significant increase in ROS level in cancer group treated with Nisin (0.51 ± 0.12) or Thoridazine (1.38 ± 0.49) or both of them (3.7 ± 0.76) compared to untreated cancer group (0.14 ± 0.03, p value< 0.001).

Statistical significant decrease in ROS level in Cancer treated with Nisin and Thoridazine compared to cancer treated with Nisin, p value = 0.01.

No significant difference between Cancer treated with Thoridazine and Cancer treated by both drugs, p value= 0.6, (Fig. 7 A).

**Anti–Angiogenic effect of Nisin and Thoridazine**

To examine effect of Nisin and/or Thoridazine on angiogenesis in HEPG2 cells, after 24 hours from treatment of HepG-2 cell line with Nisin and /or Thoridazine we measure VEGF protein level. The protein levels of VEGF were decreased significantly when HepG2 cells were treated with the combination of Nisin and Thoridazine (1.4 ± 0.22) compared with those in the groups treated with Nisin (2.4 ± 1.05) or Thoridazine (2.2 ± 0.75) only, and the untreated cancer group (5.2 ± 1.01) (p value= 0.0002), (Fig. 7 B).

No significant difference between the groups treated with Nisin or/ and Thoridazine (p value> 0.05).

**Discussion**

Hepatocellular carcinoma (HCC) is a major health problem all over the world and the number of discovered cases is more than 700,000 annually. However, there are few safe and effective therapeutic lines of treatment against HCC (28-30). The accumulating studies in cancer field supposed that combination therapies can give best result than single agents (31) Here, our study was revealed that Nisin and Thoridazine can be used as therapeutic agents against HCC alone but combination of them had better results.

Cell proliferation assessment showed that both of Nisin and Thoridazine has anti proliferative effect on HCC although Thoridazine was superior on Nisin, but combination of them had the best effect. This reduction in cell proliferation coincides with many results as Zainodini et al. proved that Nisin had anti-proliferative effect on Human.
Astrocytoma Cell Line (SW1088) (25). Also, Joo and colleagues explored the cytotoxic and antitumor properties of Nisin A and discovered that it blocks head and neck squamous cell carcinoma (HNSCC) tumorigenesis (7). In addition, Preet and colleagues demonstrated that combining doxorubicin, a conventional cancer drug, with Nisin can potentiate the effectiveness of the treatment in terms of decreasing tumor severity in skin carcinogenesis (32). Jiang et al. found that Thioridazine inhibited melanoma cells proliferation (33).

This effect may be explained by inhibition PI3K/AKT signalling in HCC cells. Our results showed decrease in PI3K/AKT gene and protein expressions. This reduction was higher in Thioridazine than Nisin but still the combination of both had the best effect. Goyette MA et al proved that thioridazine decrease tumor growth through reduction in PI3K/AKT/mTOR and ERK signaling IN Triple-Negative Breast Cancer (34). To our knowledge there is no studies test effect of Nisin on PI3K/AKT signaling pathway.

Cancer cells characterized by high levels of ROS due to malignant transformation which produce genetic, metabolic, and microenvironment changes (35). Cancer cells have the ability to accommodate high levels of ROS through antioxidant pathways activation. So, new potential agents targeting the ROS signaling pathways and redox mechanisms are tried to treat cancer. During oxidative stress, SIRT1/NRF2 signaling pathway has been proved to have principle role in regulating cellular responses (36). NRF2 is a transcription factor play important role in defense against oxidative hazards. Although, NRF2 protects healthy cells from carcinogenic agents (37), it can help cancer development by protecting cancer cells from oxidative stress through anti-oxidative stress responses (38). SIRT1 acts through the deacetylation of a number of crucial transcription factors that responsible for various biological processes, including oxidative stress (39). Our results showed that SIRT1/NRF2 decreased with different treatment especially combination between Nisin and Thioridazine suggesting that these drugs act via inhibiting anti-oxidative protective mechanisms. This inhibition leads to increase ROS level in treated groups especially in Thioridazine and drug combination. These findings coincide with Min Yong et al. (40) who found that Thioridazine produced a higher level of cellular ROS in comparison with the control group in ovarian cancer. Simultaneously, anti-oxidative stress-associated proteins were decreased, including p-Nrf2 and its downstream proteins. To our knowledge, there are no similar studies according to Nisin in cancer. But there are many studies concerned with antimicrobial effect of Nisin. Miyamoto et al. (41) examined the effect of Nisin on the Listeria monocytogenes proteome and found a higher catalase activity and amount of ferritin compared with untreated bacteria. They explained this elevated amount of antioxidant enzymes in the cells treated with Nisin to the formation of ROS. Although the activation of antioxidant mechanisms, the bacteria were not able to overcome the oxidative stress induced by antimicrobials at sublethal concentrations. Increased ROS in cancer cells may provide a good chance to kill cancer cells through elevating intracellular ROS to highly toxic levels, leading to activate various ROS-induced cell death pathways.

HCC patients have bad survival rate due to angiogenesis and metastasis (42). HCC is defined as a typical angiogenic tumor. In our study, VEGF protein level decreased with different lines of treatment especially with Nisin and Thioridazine combination compared to untreated cancer cells. There have been several studies explored the anti-angiogenic effect of Thioridazine, which have reported findings agreed with the results of our study. Thioridazine is an angiostatic agent which was found to effectively inhibit angiogenesis in a murine tumor model (43). In vitro, Thioridazine has been observed to inhibit vascular endothelial growth factor (VEGF)-induced proliferation, invasion and endothelial cell tube formation of (44).

In conclusion, the present study provided evidence that the Thioridazine and Nisin are promising effective drugs against.
Nisin and Thioridazine Anticancer Effect in HCC

hepatocellular carcinoma through inhibition of PI3K/AKT proliferation pathway, ROS induction and angiogenic inhibition. Thioridazine had superior effect than Nisin but both of them had synergistic effect with the best result. The potential for these drugs to be used in cancer therapy requires further investigation in clinical settings.

References


Acknowledgements

We would like to thank National Research Centre, Dokki, Giza, Egypt and Faculty of Medicine, Cairo University, Cairo, Egypt for all support to complete our research article.
38. van der Wijst MG, Huisman C, Mposhi A, Roelfjes G, Rots MG. Targeting Nrf2 in healthy...